Targeting a specific protein in a type of pancreatic cancer
Targeted EGFR for basal subtype pancreatic cancer
This study is looking at a tough type of pancreatic cancer called basal tumors that don’t respond well to regular treatments, and it’s exploring whether a special medicine that targets a protein called EGFR, especially when used with other therapies, can help improve the outcomes for patients dealing with this challenging condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11018567 on NIH RePORTER |
What this research studies
This research focuses on a subtype of pancreatic cancer known as basal tumors, which are resistant to standard chemotherapy. The team aims to investigate the effectiveness of targeting the EGFR protein in these tumors, as previous treatments have not been successful. By analyzing data from clinical trials, they found that patients with basal tumors may actually benefit from EGFR inhibitors when combined with other treatments. This approach seeks to improve outcomes for patients with this challenging cancer subtype through precision medicine.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with basal subtype pancreatic cancer who have not responded well to standard chemotherapy.
Not a fit: Patients with classical subtype pancreatic cancer are unlikely to benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with basal subtype pancreatic cancer.
How similar studies have performed: Previous studies have shown that targeting specific proteins in cancer treatment can lead to improved outcomes, suggesting potential success for this novel approach.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Yeh, Jen Jen — Univ of North Carolina Chapel Hill
- Study coordinator: Yeh, Jen Jen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.